BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s Managing Director Fred E. Cohen got elected

0
669

Dallas, Texas 07/25/2013 (Financialstrend) – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had announced on 24 July, 2013 that the management made declaration that Managing Director Fred E. Cohen have got elected to the firm’s board and all the directors and leadership group are very happy about it. They have also announced that Cohen brings a wealth of technical knowledge and biz approach to the company and has been invaluable resource to the group as both an advisor and as a shareholder for many years. They look forward to his leadership and insights in the direction of the further achievement of the firm.

Additionally, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had been promoted by JMP Securities and bagged Outperform position in a study note. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had previously declared its earning outcomes on May 7, 2013 and the firm registered for the quarterly period as EPS of $0.09. The income of the firm was registered as $3.60 million.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had lost 0.44% on Wednesday to close at $4.50 per share, after opening the day at a price of $4.46 per share. The stock had through the day moved with prices fluctuating between $4.31 and $5.02 per share. The company presently has 52 week low at $1.08 and 52 week high at $5.02. The institutional holding is at 32% and there are 53.15 million shares outstanding in the market with a market cap of the stock presently at $239.16 million.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biotechnology enterprise that designs, optimizes and develops drugs, which block enzymes occupied in the pathogenesis of diseases. The firm focuses on biology, crystallography, chemistry and computer modeling, therapeutic areas and the product is Peramivir that is a neuraminidase inhibitor for the treatment of patients suffering with influenza.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.